Bluefin Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-330,000
Closed -$4K 489
2018
Q4
$4K Hold
330,000
﹤0.01% 392
2018
Q3
$10K Hold
330,000
﹤0.01% 477
2018
Q2
$9K Sell
330,000
-515,000
-61% -$10.5M ﹤0.01% 391
2018
Q1
$40K Buy
845,000
+215,000
+34% +$4.2M ﹤0.01% 348
2017
Q4
$27K Buy
+630,000
New +$9.48M ﹤0.01% 410
2016
Q1
Sell
-64,400
Closed -$428K 713
2015
Q4
$428K Buy
+64,400
New +$3.98M 0.03% 323
2015
Q3
Sell
-151,800
Closed -$200K 596
2015
Q2
$200K Buy
+151,800
New +$9.36M 0.01% 436
2014
Q4
Sell
-15,000
Closed -$33K 894
2014
Q3
$33K Buy
+15,000
New +$795K ﹤0.01% 783

Other funds holding TEVA

Bluefin Capital Management's TEVA Position: Q1 2022 in Review

Bluefin Capital Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2022, closing a stake of 15,237 shares — an estimated $122K sold.

Bluefin Capital Management first reported a position in TEVA in Q3 2014 and held it in 10 quarters. The position peaked at $4.57M in Q2 2015. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

  • Bluefin Capital Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2022 after selling out during the quarter.
  • Bluefin Capital Management sold 15,237 Teva Pharmaceutical Industries Limited shares in Q1 2022, an estimated $122K.
  • Bluefin Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q3 2014 and held it in 10 quarters.
  • Bluefin Capital Management's Teva Pharmaceutical Industries Limited position peaked at $4.57M in Q2 2015.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2022.

Based on Bluefin Capital Management's 13F filing for Q1 2022, filed 16 May 2022.